Juvenile Dermatomyositis: An Overview

Juvenile dermatomyositis (JDM) is the predominant form of juvenile idiopathic inflammatory myopathies (JIIMS), accounting for up to ۸۵% of cases. This rare vasculopathic autoimmune disorder primarily affects children, manifesting as proximal muscle weakness and characteristic cutaneous rashes on the face and extensor surfaces. Epidemiologically, JDM has an incidence of approximately ۳ cases per million children annually, with a peak onset at age ۷ years and a female-to-male ratio of ۲:۱. Genetic predispositions, including HLA alleles such as DRB۱*۰۳۰۱ and DQA۱*۰۵۰۱, alongside maternal microchimerism, contribute to susceptibility. Environmental triggers, such as infections (e.g., coxsackievirus, parvovirus) and ultraviolet exposure, may precipitate disease, though no definitive etiologic agent has been identified. Pathogenetically, JDM involves autoimmune vasculopathy targeting capillaries in skin, muscle, and gastrointestinal tissues. Key mechanisms include type I interferon (IFN-a/ẞ) dysregulation, mediated by plasmacytoid dendritic cells via Toll-like receptor activation, leading to MHC class I upregulation, endoplasmic reticulum stress, and inflammatory cascades involving T cells, macrophages, and cytokines like TNF-α. Myositis-specific autoantibodies (MSAs), present in ۴۵-۵۵% of cases, define phenotypes: anti-TIF۱γ associates with severe photosensitive rashes and lipodystrophy, anti-NXP۲ with calcinosis and dysphagia; anti-MDA۵ with interstitial lung disease (ILD) and mild myopathy. Clinically, patients present with insidious weakness (۹۰-۱۰۰%), fatigue, and rashes including heliotrope eyelid discoloration (۶۶-۹۵%), Gottron papules (۵۷-۹۵%), and nail fold capillaropathy (۸۰-۹۰%). Systemic features encompass dysphagia (۱۳-۴۰%), arthritis (۲۲-۵۸%), and fever (۱۶-۶۵%). Diagnosis relies on Bohan-Peter criteria: classic rash plus three of symmetric proximal weakness, elevated muscle enzymes, electromyographic changes, or biopsy findings showing necrosis and inflammation. MRI enhances diagnostic accuracy by identifying active myositis. Differential diagnoses include polymyositis, muscular dystrophies, SLE, and infectious myositides. Laboratory findings reveal elevated enzymes (e.g., CK, aldolase), ANA positivity (۸۰%), and MSAs/MAAs guiding prognosis. Treatment emphasizes corticosteroids (prednisone ۲ mg/kg/day) with methotrexate as a steroid-sparing agent, supplemented by IVIG for refractory cases. Emerging therapies include JAK inhibitors targeting IFN pathways. Physical therapy mitigates contractures. Complications involve calcinosis (۱۲-۳۰%), lipodystrophy (۱۱-۱۴%), ILD (۱-۷%), and gastrointestinal vasculitis, often linked to delayed treatment. Prognosis has improved with immunosuppression, yielding ۱% mortality and ۷۵% minimal disability at ۷ years, though chronic rash (۴۰%) and weakness (۲۵%) persist in subsets, underscoring the need for early intervention to avert long-term vasculopathy and metabolic sequelae.